Dupilumab, as an add-on to intranasal corticosteroids, has been approved for treating adult NHS England patients with severe chronic rhinosinusitis with nasal polyps if:
• the condition is not controlled well enough by systemic corticosteroids or sinus surgery, and
• they have had at least 1 sinus surgery, and
• the 22-item sinonasal outcomes test (SNOT-22) score is at least 50
At present, Dupilumab is available from 30 hospitals in England, listed on our website here. This means that not all NHS England patients currently have access to the drug. We want to hear from anyone who is eligible for the drug but is unable to access it through their hospital/ENT service. We plan to share this information, anonymously, with the company and with NHS England in order to support widespread access to the drug for all eligible patients, wherever they are in England.
Please complete the below 5 questions. We will only use your name and email address to contact you if we have any questions.
